Vanguard Group Inc Summit Therapeutics Inc. Transaction History
Vanguard Group Inc
- $6.57 Trillion
- Q4 2025
A detailed history of Vanguard Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,177,220 shares of SMMT stock, worth $204 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,177,220
Previous 11,379,728
1.78%
Holding current value
$204 Million
Previous $236 Million
13.58%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding SMMT
# of Institutions
262Shares Held
93.5MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.13MShares$57.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...